Genomic index predicts clinical outcome of intermediate-risk XXXX , providing a new inclusion criterion for @entity2213 adjuvant therapy.

@entity1 @entity677 @entity986 @entity5 @entity406 @entity2213
PURPOSE: @entity2213 is the front-line targeted therapy for @entity5 ( @entity5 ). @entity1 's eligibility to adjuvant @entity2213 after primary @entity5 resection is currently based on histological and clinical risk assessment. While therapeutic options are clear for the very-low, low and high-risk subpopulations, no standard is actually available for the @entity5 classified as intermediate. Since we recently validated genomic index (GI), a measure of the level of genomic alterations, as a strong predictor of clinical outcome in @entity677 , we asked whether it could also represent a novel prognostic factor for the intermediate subgroup. EXPERIMENTAL DESIGN: 82 intermediate risk @entity1 were selected based on the Armed Forces Institute of Pathology (AFIP) classification for genomic profiling. RESULTS: Data revealed that even if studied samples generally harboured a combination of the typical genetic aberrations found in @entity677 , i.e. 1p, 14q 22q deletions and frequently lost @entity986 locus on chromosome 9, they profoundly differed from each other on the total number of genomic changes and GI value. Kaplan-Meier analyses of metastatic-free survival unveiled that stratification of the @entity5 by the GI value at a cutoff of 10 separated the good from the poor prognosis @entity1 , proven that metastatic-risk in @entity677 intermediate @entity1 is strongly associated with high GI values and genome complexity. CONCLUSION: GI is validated here as a robust marker to predict intermediate- @entity677 clinical outcome. Applicable in numerous Pathology Laboratories already using array comparative genomic hybridisation (CGH) with @entity406 -fixed paraffin-embedded (FFPE) samples, this assay presently stands as an efficient tool for the clinical management of intermediate @entity677 - @entity1 .
